{
    "id": 5603,
    "name": "T-cell acute lymphoblastic leukemia",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "5599"
    ],
    "termId": "DOID:5603",
    "evidence": [
        {
            "id": 4394,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, T-cell leukemia cells with over expression of Stat5b demonstrated sensitivity to pimozide in culture (Cancer Res August 1, 2015 75; 2702).",
            "molecularProfile": {
                "id": 17942,
                "profileName": "STAT5B over exp"
            },
            "therapy": {
                "id": 3499,
                "therapyName": "Pimozide",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4514,
                    "pubMedId": null,
                    "title": "Abstract 2702: Therapeutic potentials of STAT5 inhibitors in overcoming bortezomib resistance in human T-cell leukemia",
                    "url": "https://cancerres.aacrjournals.org/content/75/15_Supplement/2702"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5139,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, T-cell leukemia cells harboring PSMB5 A108T demonstrated resistance to Velcade (bortezomib) in culture (PMID: 18502982).",
            "molecularProfile": {
                "id": 20273,
                "profileName": "PSMB5 A108T"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4884,
                    "pubMedId": 18502982,
                    "title": "Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18502982"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7485,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human T cell leukemia cell line harboring both MTOR C1483Y and R2430M demonstrated hypersensitivity to Rapamune (sirolimus) induced growth inhibition in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 25517,
                "profileName": "MTOR C1483Y MTOR R2430M"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20119,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring PSMB5 C111F demonstrated resistance to treatment with Velcade (bortezomib) in culture (PMID: 21941364).",
            "molecularProfile": {
                "id": 32046,
                "profileName": "PSMB5 C111F"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14921,
                    "pubMedId": 21941364,
                    "title": "Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21941364"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20427,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DT2216 treatment resulted in decreased BCL-XL expression and increased apoptosis and reduced viability of a T-cell acute lymphoblastic leukemia (T-ALL) cell line in culture, and decreased tumor growth in xenograft models (PMID: 31792461).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9340,
                "therapyName": "DT2216",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17825,
                    "pubMedId": 31792461,
                    "title": "A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31792461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20434,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DT2216 to therapy with Oncovin (vincristine), dexamethasone, and Elspar (asparaginase) resulted in increased survival in a chemotherapy-resistant patient-derived xenograft (PDX) model of T-cell acute lymphoblastic leukemia that expressed high levels of BCL2, MCL1, and BCL-XL (BCL2L1) (PMID: 31792461).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9351,
                "therapyName": "Asparaginase + Dexamethasone + DT2216 + Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17825,
                    "pubMedId": 31792461,
                    "title": "A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31792461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21275,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tyrphostin B42 (AG-490) inhibited proliferation of T-cell acute lymphoblastic leukemia cells harboring a JAK1 nonsense mutation and TYK2 E957D in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 36165,
                "profileName": "JAK1 inact mut TYK2 E957D"
            },
            "therapy": {
                "id": 2783,
                "therapyName": "Tyrphostin B42",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21276,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pyridone 6 (CMP6) inhibited proliferation of T-cell acute lymphoblastic leukemia cells harboring a JAK1 nonsense mutation and TYK2 E957D in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 36165,
                "profileName": "JAK1 inact mut TYK2 E957D"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21277,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, T-cell acute lymphoblastic leukemia cells harboring a JAK1 nonsense mutation and TYK2 E957D demonstrated resistance to Xeljanz (tofacitinib) in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 36165,
                "profileName": "JAK1 inact mut TYK2 E957D"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02112916",
            "title": "Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1441,
                    "therapyName": "Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 1638,
                    "therapyName": "Pegaspargase",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1640,
                    "therapyName": "Mercaptopurine",
                    "synonyms": null
                },
                {
                    "id": 1641,
                    "therapyName": "Thioguanine",
                    "synonyms": null
                },
                {
                    "id": 1642,
                    "therapyName": "Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 1006,
                    "therapyName": "Daunorubicin",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02518113",
            "title": "A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 2958,
                    "therapyName": "LY3039478",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04128501",
            "title": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1637,
                    "therapyName": "Azacitidine + Venetoclax",
                    "synonyms": null
                }
            ]
        }
    ]
}